Loading
A phase 3 trial of Toremifene in Prostate cancer, run by GTx, completed.
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy is a phase 3 interventional study registered as NCT00129142 by GTx, with 1200 participants recorded, started 2003-10 and reaching its primary completion in 2007-11. Interventions recorded: Toremifene Citrate. Conditions recorded: Prostate Cancer, Osteoporosis, Fractures.
Linked to the drug Toremifene because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toremifene and the tag pipeline.
Shares Toremifene and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/